To observe the effects of MYC loss in ALK+ NSCLC, we employed RNAi technology to silence MYC in ALK+ cell lines and measured the proliferation in response to crizotinib (Figure 5A). This evidence concerns the gene MYC and non-small cell lung carcinoma.